For COVID-19 therapeutics, two proteins that played an essential role in the virus’s cell-entry process are the human angiotensin-converting enzyme 2 (hACE2) and the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 [23], [24]. This evidence concerns the gene ACE2 and COVID-19.